Explore

Rapid Read Rapid Read
FDA Approves Freenome's SimpleScreen CRC Blood-Based Test for Colorectal Cancer Screening

FDA Approves Freenome's SimpleScreen CRC Blood-Based Test for Colorectal Cancer Screening

The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer (CRC) in adults aged 45 and older who are at average risk. This test, which will be commercialized by Abbott in the U.S., offers a new option for CRC screening that requires only a simple blood draw. The approval follows extensive clinical research and collaboration, including the PREEMPT CRC study, which enrolled over 48,000 participants. SimpleScreen CRC demonstrated 81.1% sensitivity in detecting colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. The test aims to increase screening rates among the estimated 60 million Americans overdue for CRC screening.
Rapid Read Rapid Read
IntelliGenome Partners with Cornell University to Develop Portable TB Diagnostic Solution

IntelliGenome Partners with Cornell University to Develop Portable TB Diagnostic Solution

IntelliGenome, a leader in CRISPR-based in vitro diagnostic technology, has announced a research and development subaward agreement with Cornell University. This collaboration aims to develop a rapid, low-cost, and portable diagnostic solution for tuberculosis (TB). The project is part of a National Institutes of Health (NIH)-funded program focused on enhancing access to innovative health technologies. The initiative will utilize IntelliGenome's point-of-care testing (POCT) platform to detect cell-free DNA from Mycobacterium tuberculosis in both respiratory and blood samples. This approach seeks to address the limitations of current TB diagnostic methods, which often rely on sputum samples and centralized laboratory workflows, potentially delaying treatment. The new solution integrates sample processing with CRISPR-based detection, aiming to provide faster and more accessible testing, especially in areas with limited laboratory infrastructure.
Rapid Read Rapid Read
Experts Establish Standards for Vocal Biomarkers in Disease Prediction

Experts Establish Standards for Vocal Biomarkers in Disease Prediction

Researchers from the Luxembourg Institute of Health and the University of South Florida have developed a consensus-based framework for vocal biomarkers, which are indicators derived from voice recordings that can signal various health conditions. This initiative, part of the VOCAL project, aims to standardize terminology and methodologies in the field, addressing inconsistencies that have arisen due to the rapid growth of voice-based health technologies. The framework distinguishes between vocal measures and validated biomarkers, providing a structured vocabulary to enhance collaboration among researchers, clinicians, and industry stakeholders.
Rapid Read Rapid Read
Masimo's Pediatric Sedation Monitoring System Gains FDA Clearance

Masimo's Pediatric Sedation Monitoring System Gains FDA Clearance

Masimo, a company specializing in patient-monitoring solutions, has received FDA 510(k) clearance for its Pediatric Patient State Index (PSi), a sedation monitoring system specifically designed for the pediatric brain. This system is part of Masimo's SedLine brain function monitoring technology and is intended to help clinicians accurately monitor the depth of sedation in children aged four years and older. The pediatric PSi is the first index derived from bilateral brain data and is calibrated for use with common anesthetic drugs like propofol and sevoflurane. This development addresses the challenge of monitoring sedation in children, whose brains respond differently to anesthesia compared to adults.
Trendline Trendline
Longevity Clinics Embrace Preventative Medicine to Extend Healthspan

Longevity Clinics Embrace Preventative Medicine to Extend Healthspan

Longevity Clinics Embrace Preventative Medicine to Extend Healthspan
Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Rapid Read Rapid Read
Future ICU Management to Integrate AI and Virtual Reality for Enhanced Care

Future ICU Management to Integrate AI and Virtual Reality for Enhanced Care

By 2050, intensive care units (ICUs) are expected to transform into distributed, technology-enabled systems that integrate artificial intelligence (AI), automation, and tele-ICU capabilities. These advancements aim to improve early detection of patient deterioration, personalize treatment, and enhance overall efficiency. The integration of virtual reality (VR) in critical care is also emerging, offering potential benefits in symptom management and clinician training. However, the successful implementation of these technologies will require overcoming challenges related to data integration, regulatory compliance, and workforce adaptation.
Rapid Read Rapid Read
Curebound Expands Leadership Team to Boost Cancer Research Efforts

Curebound Expands Leadership Team to Boost Cancer Research Efforts

Curebound, a cancer research accelerator based in San Diego, has announced the appointment of three key executives to its leadership team. Mary Meyer joins as Chief Advancement Officer, Scotty Cadet, Ph.D., as Chief Scientific Officer and Vice President of Research, and Leena Gupta as Chief Financial Officer. These appointments aim to enhance Curebound's fundraising, scientific leadership, and financial strategy. Meyer brings extensive experience in philanthropy, Cadet in cancer research and drug development, and Gupta in financial management for nonprofits. The new team is expected to drive Curebound's mission of advancing early cancer detection and personalized therapies.
Trendline Trendline
Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments
Rapid Read Rapid Read
FDA Approves Freenome's Blood-Based Colorectal Cancer Screening Test for U.S. Market

FDA Approves Freenome's Blood-Based Colorectal Cancer Screening Test for U.S. Market

The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer. This test, which will be commercialized by Abbott in the U.S., offers a new option for adults aged 45 and older who are at average risk for colorectal cancer. The approval follows the PREEMPT CRC study, the largest clinical validation study for a blood-based colorectal cancer screening test, involving over 48,000 participants. SimpleScreen CRC detects cancer signals from cell-free DNA in the blood, providing a non-invasive alternative to traditional colonoscopy.
Rapid Read Rapid Read
UNC Researchers Develop Light-Activated Cancer Treatment to Minimize Side Effects

UNC Researchers Develop Light-Activated Cancer Treatment to Minimize Side Effects

Researchers at the University of North Carolina at Chapel Hill are exploring a novel approach to cancer treatment that aims to reduce the chronic side effects often associated with traditional therapies. Led by Brianna Vickerman, a research assistant professor at the UNC Eshelman School of Pharmacy, the team is developing a method that uses light to activate cancer drugs only at the disease site. This technique involves encapsulating existing medications into carriers that circulate through the body without affecting healthy tissues. When the disease area is illuminated, the carriers release the drug precisely where needed. This approach builds on previous research involving light-controlled drug delivery for cardiovascular diseases. The project recently received a two-year commercialization-focused innovation grant to further test the technology in cancer models, with the ultimate goal of clinical development.
Trendline Trendline
Neko Health's Full-Body Scan Gains Popularity Amid Wellness Trends

Neko Health's Full-Body Scan Gains Popularity Amid Wellness Trends

Neko Health's Full-Body Scan Gains Popularity Amid Wellness Trends